This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Are Medical Stocks Lagging Alcon (ALC) This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for October 23rd
by Zacks Equity Research
MNTX, IPA, AHT, VCEL and ALPN have been added to the Zacks Rank #1 (Strong Buy) List on October 23, 2023.
Is it a Good Idea to Invest in Dynavax (DVAX) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Dynavax Technologies (DVAX) stock now may turn out to be a prudent move.
Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug
by Zacks Equity Research
CHMP gives a positive opinion to Merck (MRK) for the expanded use of Prevymis to help prevent CMV disease in high-risk kidney transplant patients.
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
by Zacks Equity Research
Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.
Lilly (LLY) Up on NVO's Ozempic Early Success in Kidney Study
by Zacks Equity Research
Eli Lilly's (LLY) Mounjaro is also being evaluated in clinical studies for patients who are obese or overweight and have CKD. Investors are probably expecting similar success with Mounjaro's CKD study.
Amgen's (AMGN) Stock Rallies Almost 5% on Broker Upgrade
by Zacks Equity Research
A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).
Merck's (MRK) Keytruda Early-Stage NSCLC Study Shows OS Benefit
by Zacks Equity Research
Merck's (MRK) phase III study on Keytruda shows a statistically significant overall survival benefit for patients with stage II, IIIA or IIIB NSCLC.
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
by Zacks Equity Research
J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive NSCLC.
Wall Street Analysts Believe Alpine Immune Sciences, Inc. (ALPN) Could Rally 50.37%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Alpine Immune Sciences, Inc. (ALPN) points to a 50.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker
by Zacks Equity Research
AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.
Sanofi (SNY) Stock Outperforms Industry YTD: What's Next?
by Zacks Equity Research
Continued strong sales of Dupixent, contributions from new product launches and positive pipeline progress are likely to keep Sanofi's (SNY) stock afloat.
Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio
by Zacks Equity Research
Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.
AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M
by Zacks Equity Research
AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
by Zacks Equity Research
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
Here's Why You Should Invest in Alpine (ALPN) Stock Now
by Zacks Equity Research
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Has SiBone (SIBN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Si-Bone (SIBN) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alpine Immune Sciences, Inc. (ALPN) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.